The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program
Health Affairs · 01.05.2023 · 42 (5) · 632-641
DOI: 10.1377/hlthaff.2022.00812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.05.2023. Verfasst von Amelia M Bond und 2 weiteren Autor:innen. Beteiligte Einrichtung: Amelia M. Bond (amb2036@med.cornell.edu), Cornell University, New York, New York. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Medicare, Reimbursement, Incentive. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AHRQ HHS.
Abstract (Originalsprache)
Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. However, rates of biosimilar uptake have varied across hospital outpatient providers. We investigated whether the 340B Drug Pricing Program, which offers eligible hospitals substantial discounts on drug purchases, inhibits biosimilar uptake. Almost one-third of US hospitals participate in the 340B program. Using a regression discontinuity design and two high-volume biologics with biosimilar competitors, filgrastim and infliximab, we estimated that 340B program eligibility was associated with a 22.9-percentage-point reduction in biosimilar adoption. In addition, 340B program eligibility was associated with 13.3 more biologic administrations annually per hospital and $17,919 more biologic revenue per hospital. Our findings suggest that the program inhibited biosimilar uptake, possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amelia M. Bond (amb2036@med.cornell.edu), Cornell University, New York, New York.
- Emma B. Dean, University of Miami, Miami, Florida.
- Sunita M. Desai, New York University, New York, New York.
Förderung
- AHRQ HHS
Zitieren
APA
Bond, A. M., Dean, E. B., & Desai, S. M. (2023). The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program. Health Affairs, 42(5), 632-641. https://doi.org/10.1377/hlthaff.2022.00812
Vancouver
Bond AM, Dean EB, Desai SM. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program. Health Affairs. 2023;42(5):632-641. doi:10.1377/hlthaff.2022.00812
BibTeX
@article{Bond2023,
author = {Bond, Amelia M and Dean, Emma B and Desai, Sunita M},
title = {The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program},
journal = {Health Affairs},
year = {2023},
volume = {42},
number = {5},
pages = {632--641},
doi = {10.1377/hlthaff.2022.00812}
}
EUVIMED